# A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

> **NCT05208762** · PHASE1 · RECRUITING · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 714 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Squamous Cell Carcinoma of the Head and Neck
- Esophageal Squamous Cell Carcinoma
- Triple Negative Breast Neoplasms
- Gastric Cancer
- Endometrial Cancer
- Pancreatic Adenocarcinoma
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** PF-08046054
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT05208762
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-25
- **Primary completion:** 2028-01-05
- **Final completion:** 2029-01-04
- **Target enrollment:** 714 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05208762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05208762, "A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05208762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*